Get the Stockscreener App
61.97
3.16%
-2.02
After Hours:
61.97
Crispr Therapeutics Ag stock is traded at $61.97, with a volume of 1.92M.
It is down -3.16% in the last 24 hours and down -8.52% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$63.99
Open:
$63.02
24h Volume:
1.92M
Relative Volume:
0.77
Market Cap:
$5.64B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-22.13
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-5.71%
1M Performance:
-8.52%
6M Performance:
+62.01%
1Y Performance:
+22.08%
1-Day Range:
$60.53
$64.74
1-Week Range:
$60.53
$65.98
52-Week Range:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
61.97 | 5.82B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | JP Morgan | Overweight |
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? - Zacks Investment Research
Is CRISPR Therapeutics AG showing signs of accumulationTrade Volume Summary & Fast Entry and Exit Trade Plans - newser.com
What to do if you’re stuck in CRISPR Therapeutics AGJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com
Has CRISPR Therapeutics AG found a price floorQuarterly Earnings Summary & Reliable Momentum Entry Alerts - newser.com
CRISPR Therapeutics AG stock trendline breakdownPortfolio Performance Report & High Return Trade Opportunity Guides - newser.com
Why retail investors favor CRISPR Therapeutics AG stock2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Why CRISPR Therapeutics AG stock could rally in 2025July 2025 Decliners & Verified Momentum Stock Ideas - newser.com
How to build a dashboard for CRISPR Therapeutics AG stockJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Visualizing CRISPR Therapeutics AG stock with heatmapsTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Can CRISPR Therapeutics AG (1CG) stock double in coming yearsJuly 2025 Catalysts & Community Consensus Stock Picks - newser.com
Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsJuly 2025 Closing Moves & Momentum Based Trading Signals - newser.com
Applying Wyckoff theory to CRISPR Therapeutics AG stock2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
Key resistance and support levels for CRISPR Therapeutics AG2025 Market Sentiment & Community Consensus Trade Alerts - newser.com
How big funds are accumulating CRISPR Therapeutics AG (1CG) stock2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Why CRISPR Therapeutics AG (1CG) stock is listed among top recommendationsQuarterly Trade Report & Smart Swing Trading Techniques - newser.com
Will CRISPR Therapeutics AG (1CG) stock gain from green policies2025 Market Trends & Technical Confirmation Trade Alerts - newser.com
What valuation multiples suggest for CRISPR Therapeutics AG stock2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsMarket Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
Y Intercept Hong Kong Ltd Makes New $1.91 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 6,003 CRISPR Therapeutics AG $CRSP - MarketBeat
Is CRISPR Therapeutics AG stock a buy for dividend growthJuly 2025 Rallies & Low Drawdown Investment Strategies - newser.com
Is CRISPR Therapeutics AG stock a top pick in earnings seasonJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway - GuruFocus
Gene editing therapy companies rise on word of streamlined FDA approval process - Seeking Alpha
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP - GuruFocus
FDA Clears Way for Faster Personalized Gene Editing Therapy - Bloomberg.com
Key metrics from CRISPR Therapeutics AG’s quarterly dataWeekly Trend Report & AI Forecasted Stock Moves - newser.com
Visual analytics tools that track CRISPR Therapeutics AG performanceQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
Assessing CRISPR Therapeutics After First US Gene-Editing Therapy Spurs 47.5% Stock Surge - Sahm
Building trade automation scripts for CRISPR Therapeutics AG2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):